Hereditary Kidney Disease
Cross-source consensus on Hereditary Kidney Disease from 1 sources and 5 claims.
1 sources · 5 claims
Where it comes from
Other
Other
Highlighted claims
- Patients with comorbid diabetes are excluded from the trial. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- Eligible participants generally need a hereditary kidney disease diagnosis confirmed by molecular genetic testing. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- Eligible patients must have proteinuria above the protocol threshold and preserved eGFR. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- Hereditary kidney diseases and congenital anomalies account for most childhood CKD cases. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- Alport syndrome can qualify without molecular confirmation when clinical, pathological, and family-history evidence supports the diagnosis. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)